News

Wellcome Trust invests a £200m VC
Enlarge image

FundingUK

Wellcome Trust invests a £200m VC

04.01.2013 - The Wellcome Trust’s new venture capital unit Syncona Partners LLC pours £200m into early stage healthcare start ups.

The world’s second largest charity plans to invest between £1m-£20m in each of its future portfolio companies as announced last spring. According to Wellcome's annual report last month, Syncona has already made one investment. The directly owned and managed investment firm combines the trust’s experience in the health and biotechnology sectors with its investment expertise. While Syncona offers a new source of finance and guidance for healthcare businesses at an early stage of their development, the trust hopes to make some return on investment to fuel its pipeline of charitable projects.

“We expect to play our part in building successful businesses based upon innovation within the life science and health-care industry,” Syncona Chief Executive Officer Martin Murphy said in a statement. According to the Trust’s annual report, its role is becoming an increasingly global one. It disclosed that UK assets now account for a mere 6% of its £14.5bn investment portfolio, down from 13% in 2009 and 33% in 2006. Hence the portfolio “has hardly suffered from the underperformance of European assets in the financial crisis.” The influential investor has also cut its assets in Europe, with the proportion of its portfolio invested in the continent falling to 13% (2009: 22%; 2006: 48%). The charity said that it envisaged better returns from faster-growing nations in Asia and Latin America.

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2013-01/wellcome-trust-invests-a-pound200m-vc.html

EU

04.09.2015 Crowdfinancing has just recently emerged as a financing instrument in the Life Sciences. A new report lists 42 European companies in the sector that have raised a total of almost €23m.

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOLVA (CH)1.49 CHF12.03%
  • TIGENIX (B)1.23 EUR9.82%
  • OREXO (S)49.10 SEK8.39%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-11.67%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • PROTHENA PLC (IE)52.70 USD-6.54%

TOP

  • KARO BIO (S)41.90 SEK2568.8%
  • BIOTECH PHARMACON (N)16.80 NOK80.6%
  • TRANSGENE (F)4.86 EUR75.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-49.6%
  • THROMBOGENICS (B)2.85 EUR-42.1%

TOP

  • KARO BIO (S)41.90 SEK4661.4%
  • ADOCIA (F)89.30 EUR409.1%
  • GALAPAGOS (B)53.25 EUR325.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-81.7%
  • BIOTEST (D)20.30 EUR-76.5%

No liability assumed, Date: 03.09.2015